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ABSTRACT 
 
Background: Histamine (HA) is a small amine playing an important role in anaphylactic 
reactions. In order to identify and quantify HA in plasma matrix, different methods have been 
developed but present several disadvantages. Here, we developed an alternative method using 
liquid chromatography coupled with an ultra-high resolution and accurate mass instrument, Q 
ExactiveTM (Thermofisher) (LCHRMS). 
Methods: The method includes a protein precipitation of plasma samples spiked with HA-d4 
as internal standard (IS). LC separation was performed on a C18 Accucore column (100*2.1 
mm, 2.6 μm) using a mobile phase containing nonafluoropentanoic acid (3 nM) and 
acetonitrile with 0.1% (v/v) formic acid on gradient mode. Separation of analytes was obtained 
within 10 min. Analysis was performed from full scan mode and targeted MS2 mode using a 5 
ppm mass window. Ion transition monitored for targeted MS2 mode were 
112.0869>95.0607m/z for HA and 116.1120>99.0855m/z for HAd4. Calibration curves were 
obtained by adding standard calibration dilution at 1 to 180 nM in TrisBSA. 
Results: Elution of HA and IS occurred at 4.1 min. The method was validated over a range of 
concentrations from 1 nM to 100 nM. The intra- and inter-run precisions were <15% for 
quality controls. Human plasma samples from 30 patients were analysed by LCHRMS, and 
the results were highly correlated with those obtained using the gold standard 
Radioimmunoassay (RIA) method. 
Conclusion: Overall, we demonstrate here that LCHRMS is a sensitive method for histamine 
quantification in biological human plasmas, suitable for routinely use in medical laboratories. In 
addition, LCHRMS is less time-consuming than RIA, avoid the use of radioactivity, and 
could then be considered as an alternative quantitative method. 
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Abbreviations: HA: Histamine 
LCHRMS: Liquid Chromatography - High Resolution - Mass Spectrometry NFPA: 
Nonafluoropentanoic acid 
RIA: Radioimmunoassay 
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1. Introduction 
 
Histamine (HA) (M = 111.1451 g.mol-1) had been discovered in 1910 by Dale and Laidlaw 
[1]. HA is a small organic nitrogenous molecule known to play an important role in allergic 
reactions. Indeed, mast cells and basophils are specifically prone to synthetize HA, and to 
secrete it after IgE-dependent activation and degranulation during type I hypersensitivity 
responses. Binding of HA to its four different receptors [histamine 1 receptor (H1R), H2R, 
H3R and H4R] present on various cells in different tissues has been associated with clinical 
symptoms and metabolic functions. It is now well documented that binding of HA to H1R 
and/or H2R leads to vasodilatation, blood pressure diminution, mucus secretion, or even 
gastric acid secretion. Due to H3R ligation, HA plays a role in various neurological processes 
such as food intake or memory, and in neuropathology [2]. As described by Rosa and Fantozzi 
[3], HA could play an important role in neurogenic inflammation, particularly in nociceptive 
pain but also in neurogenic inflammation of skin, airways and bladder. Finally, many findings 
confer to HA a physiologic role during pregnancy [4][5]. 
During type I hypersensitivity responses, only 2 biological markers seem relevant and are 
currently quantified in routine laboratories to validate the allergic reaction: HA and tryptase. 
HA release could be measured in plasma, but also in other matrix such as urine [6], 
cerebrospinal fluid [7], or even cell culture supernatant [8]. Due to HA low concentrations in 
these different fluids even after an important release, sensitive quantification methods are 
needed. Various analytical methods have already been developed to identify and quantify HA in 
biological samples: liquid chromatography (LC) [9][10], gas chromatography (GC) [11][12], 
capillary electrophoresis (CE) [13] coupled with different detection modes. Derivatization was 
usually used to improve the sensitivity, but was time-consuming, and increased the risk of low 
analyte recovery. Other non-separative methods like radioimmunoassay (RIA) [14][15] or 
enzyme immunoassays (EIA) [16] are currently the most common methods used in medical 
laboratories. RIA is yet considered as the gold standard method. However, RIA is highly 
time-consuming, and protective measures against radiations and exposure monitoring of the 
technicians due to use of radioactivity are necessary. In addition, cross reactivity with 3- 
methylhistamine, the main metabolite of HA in vivo, is still an issue for RIA and EIA 
methods [17]. 
The definition of new methods combining high resolution and high throughput analyses could 
be useful. To our knowledge, no method using Liquid Chromatography - High Resolution - 
Mass Spectrometry (LCHRMS) to quantify HA in plasma samples has been yet developed 
and validated for medical laboratory application. Herein, we describe a validated method 
using liquid chromatography coupled with an ultra-high resolution and accurate mass 
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instrument (Q ExactiveTM) for HA quantification in plasma from patients suspected to develop 
an anaphylactic reaction. This method was compared to the RIA gold standard method, and was 
found to be routinely usable in medical laboratories. 
 
2. Experimental 
2.1 Chemicals and reagents 
 
Histamine (HA) (C5H9N3), nonafluoropentanoic acid (NFPA), sulfosalycylic acid (SSA), 
trifluoroacetic acid (TFA), Tris, NaCl, KCl, CaCl2, MgCl2 and Bovine Serum Albumin (BSA) 
were obtained from Sigma-Aldrich (St Quentin Fallavier, France). Acetonitrile (ACN) was 
obtained from Thermo Fisher (Elancourt, France). Deuterated Histamine (HAd4) (Histamine- 
α,α,β,β-d4), the internal standard (IS), was obtained from C/D/N Isotopes (Quebec, Canada). 
TrisBSA solution was prepared as follow: 3.02859g of Tris, 7.0128g NaCl, 0.3728g KCl, 
0.0445g CaCl2, 0.1016g MgCl2, and 0.3g BSA were dissolved in 1 litre of water. All chemicals, 
reagents and solvents were of LC/MS quality grade. 
 
2.2 Instrumentation 
 
Analyses were performed on a Thermo Scientific Q ExactiveTM (San Jose, USA) mass 
spectrometer including an Accela pump (Thermo Scientific, San Jose, USA). A heated 
electrospray ionisation-II (HESI-II) ion source was used for the ionization of target 
compounds. Data acquisition, peak integration and calibration were performed using 
Xcalibur® 2.1 software (ThermoScientific, San Jose, CA, USA). 
 
2.3 LC conditions 
 
LC separation was performed using a C18 Accucore column (100 mm*2.1, 2.6 μm) 
(ThermoScientific, San Jose, CA, USA) thermostated at 40°C. The mobile phases used were 
NFPA (3 mmol.L-1; solvent A) and ACN with 0.1% (v/v) formic acid (solvent B) in a 
mobile phase as described in Table 1. All prepared samples were kept at 15°C in the 
auto-sampler until injection of 20μL into the LCHRMS system (full loop). Sampling 
needle was washed with a flush (75%ACN, 25% water containing 0.1% TFA). 
 
2.4 MS conditions 
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The source HESI-II was set up as follow: probe at 300°C was operated in positive 
electrospray ionization mode with spray voltage of 3kV, sheath gas and auxiliary gas (N2) 
were pressurized at 40 psi and 10 arbitrary units respectively, capillary temperature was set at 
300°C and source lens at 60V. Data were acquired simultaneously in full scan with high- 
resolution acquisition and targeted MS2 modes. In full scan acquisition, resolution was set at 
70000 FWHM. The C-trap capacity was set at 106 charges and the maximum injection time at 
200ms. The mass range was set from 100 to 123 m/z. In targeted MS2 mode, resolution was 
set at 17500 FWHM. The C-trap capacity was set at 5.105 charges and the maximum injection 
time at 100ms. The isolation window was set at 1.0 m/z and the normalized collision energy at 
45%. In full scan mode, the exact mass of each protonated species (112.0869 for HA and 
116.1120 for HAd4) was extracted for quantification, using a 5 ppm extraction window. In 
addition, to be sure of the specificity and selectivity of the used quantifier mass, one ion 
transition was monitored per compound in fragmentation mode (HA: 112.0869>95.0607 m/z; 
and HAd4: 116.1120>99.0855 m/z). 
 
2.5 Standard solutions for LCHRMS 
 
Stock solutions of HA (100 μM) and the IS HAd4 (10 μM) were prepared by dissolving each 
accurately weighed compound in a known volume of de-ionized water, and were stored at - 
80°C. HA calibration standard solutions (1, 5, 20, 60, 120 and 180 nM) were daily prepared by 
dilution of the stock solution of HA with de-ionized water. Working IS solution (25 nM) was 
prepared by dilution of the stock IS solution in de-ionized water. 
 
2.6 Quality Controls preparation 
 
Quality control (QC) samples were prepared at three concentrations of HA (3, 30 and 150 nM) 
by fortifying TrisBSA solution, and stored at -80°C. 100μL of QC was added to 250μL of de- 
ionized water and 100μL of IS. SSA (50μL at 20% v/v) was added in each tube for protein 
precipitation before vortexing for 30 seconds. After centrifugation at 3000g for 10 minutes at 
4°C, 200μL of supernatant were transferred to an auto-sample vial. 
 
2.7 Calibration and linearity 
 
100μL of each calibration standard solution was added to 100μL of TrisBSA, 150μL of de- 
ionized water, 100μL of IS, and 50μL of SSA at 20% (v/v). After extraction, the six calibration 
points were analysed. Standard curves corresponded to peak area ratios of HA to IS using 
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weighted linear least-squares regression (1/x), and coefficients of determination (r²) were 
calculated. Mean and standard deviation (SD) were calculated from six calibration curves 
run each day, and precision was represented by the coefficient of variation 
(CV=100*SD/mean) between each calibration point run 6 times. 
 
2.8 Recovery, process efficiency and matrix effect 
 
Recovery (RE), matrix effects (MEs), and process efficiency (PE) were performed in QC 
samples at 3 concentrations (3, 30 and 150 nM) in analogy to the simplified approach 
described by [18] et al . Briefly, RE was calculated by comparing average peak areas of 
TrisBSA fortified by the same concentrations of QC samples, before or after the extraction 
procedure. PE was determined by comparing average peak areas of TrisBSA fortified prior to 
extraction with peak areas of samples at the same nominal concentrations prepared in water 
(neats). MEs were calculated as follows: (100 * mean peak area of fortified TrisBSA after 
extraction / mean peak area of neats) – 100. 
 
2.9 Precision and accuracy 
 
The repeatability (intraday precision) was evaluated by analysing 6 different samples of each 
QC concentration (3, 30, 150 nM) in the same day. For reproducibility (interday precision), 10 
different day analyses were assessed for the 3 QC samples. The calculated values were based 
on a daily calibration curve. Precision was calculated by using the coefficient of variation (CV 
% = (SD/M)*100); where M is the mean of the experimentally determined concentrations and 
SD the standard deviation of M and the bias was used to express accuracy [19]. The assay 
acceptance criterion for each concentration was ± 15% deviation of the nominal concentration, 
except for the lower limit of quantification (LLOQ) for which a deviation of ± 20% was 
accepted. 
 
2.10 Stability 
 
Long-term stability of stock solutions was evaluated by comparing stored and fresh stock 
solutions. Long-term stability of HA was checked by measuring QC samples (3, 30, and 
150 nM) stored at -80°C during 6 months using a daily calibration curve. The stability of HA 
after extraction was tested on the same extract injected at the beginning and at the end of an 
analytical run of 12 hours. This stability was checked at 3 levels (3, 30 and 150 nM) of spiked 
plasma. 
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2.11 Method validation 
 
Institutional review board approval was obtained for the use of human plasma samples, 
according to the Declaration of Helsinki. Thirty plasma samples obtained from Rennes 
University Hospital patients between February 2010 and February 2013 were analysed using 
RIA method. Residual plasma samples were re-analysed by LCHRMS method, and results 
were compared to RIA values. Blood was collected in EDTA tubes, and plasma was separated 
by centrifugation at 3000g for 10 minutes. Then, plasma was aspirated gently with respecting a 
security merge of 1cm from the buffy coat to avoid contamination by white blood cells, and 
was frozen at -80°C until assayed. Samples have been stored at -80°C until analysis and 
treated by the same number of freeze-thaw cycles. HA quantification by RIA in plasma was 
realised using RIA Histamine kit (Immunotech, Marseilles, France) according to the 
manufacturer’s procedure. 
For HA quantification using the in-house LCHRMS method, plasma samples were prepared as 
QC: 100μL of plasma sample were added to 250μL of de-ionized water and 100μL of IS. 
Sulfosalicylic acid (SSA) (50μL at 20% v/v) was added in each tube for protein precipitation 
before vortexing for 30 seconds. After centrifugation at 3000g for 10 minutes at 4°C, 200μL 
of supernatant were transferred to an auto-sample vial. 
 
2.12 Statistical analysis 
 
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA) and Excel software were 
used to perform statistical analyses. LCHRMS and RIA were compared using a Spearman 
correlation analysis. Results are expressed as means ± SD. A p-value of less than 5% was 
considered statistically significant. 
 
3. Results 
 
During method development, different procedures have been evaluated to optimize sample 
extraction, matrix effect, chromatographic and detection parameters. Sample preparation, 
extraction and chromatographic conditions have been carefully optimized for simple, rapid and 
practical quantitative analyse, avoiding most of matrix effects. 
 
3.1 Chromatography and detection 
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Mass spectra showing the selected precursor and product ion used for detection of HA and 
deuterated Histamine (HAd4) are presented in Figure 1. The precursor ion of HA displays an 
m/z of 112.0871 which is an error of 1.57 ppm with the theoretical mass assigned by X-Calibur, 
([Observed Ion Mass— Theoretical Ion Mass] / Theoretical Ion Mass) x 106. Its primary 
product ion has an m/z of 95.0607. The precursor ion of HAd4 shows an m/z of 116.1120, 
and its primary product ion an m/z of 99.0855. Representative LCHRMS chromatograms of 
samples are shown in Figure 2. Each chromatogram represented the two modes of acquisition 
in full scan and targeted MS2. The first mode allows the quantification and the second 
confirms specific detection. HA and HAd4 have the same retention time of 4.1 min (Figure 
2). We hypothesize that the small peak at 4.3 min corresponds to a stereoisomer. 
Chromatograms of protonated histamine (HA) and HAd4, obtained by full scan acquisition 
and targeted MS2 mode using a 5 ppm mass window for a human plasma sample 
(approximatively 20 nM) 
 
3.2 Calibration curve and linearity 
 
The six-point calibration curve for histamine was linear over the range of 1 to 180 nM with 
CVs ranging from 1.6 to 8.1%. The linearity was verified with a lack of fit test and the r² 
coefficient of determination was >0.99. Typical equation of calibration curve was: y = 0.9902x 
+ 0.9735. The LLOQ was determined to be 1 nM (CV = 8.1%). 
 
3.3 Recovery, process efficiency and matrix effect 
 
RE was determined between 102.1 and 114.9%. In this procedure, ME was determined to be 
lower than 3%. Also, PE has been calculated at +11.4%, +7.8% and -0.5% respectively for 3, 
30 and 150 nM QC samples. 
 
3.4 Precision and Accuracy 
 
Six aliquots of each QC samples (3, 30, 150 nM) were tested in the same run to evaluate 
repeatability. Mean, SD, CVs, and biases are reported to be acceptable (table 2). The inter-day 
evaluation of QC samples tested once a day (n=10) showed a good reproducibility (Table 3). 
All CVs were inferior to 10% for the 3 levels (8.7, 6.1 and 3.4% for 3, 30 and 150 nM QC 
samples, respectively) and biases were between 0.2 and 6.1%. The precision and accuracy 
were in conformity with the related rules of biological sample analysis method guidelines 
[20]. 
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3.5 Stability 
 
Using our validated method, we assessed the stability of HA under various conditions. 
Concerning the stability of stock solutions at -80°C, we did not observe any decrease in HA 
concentration after 1 year of storage. The stability of QC samples at -80°C was also excellent 
for the three QC samples. For instance, 8 months after preparation and with a new calibration 
solution, the 3, 30 and 150 nM QC samples showed measured values of 3.00, 30.09, and 
161.4 nM, respectively. In addition, mean concentrations over 8 months were 2.99 (CV = 
3.46%), 31.02 (CV = 2.85%) and 157.84 nM (CV = 2.90%). Finally, HA stability after 
extraction also showed that no significant degradation occurred during auto-sampler at 15°C 
for 12h before analysis. A decrease of 7.3, 2.5 and 5.5% was observed for the 3 QC samples 
(3, 30 and 150 nM, respectively). 
 
3.6 Plasma sample analysis and comparison with RIA 
 
HA concentration of plasma samples from patients has been evaluated using our validated 
LCHRMS method, and compared to the concentration obtained with the gold standard RIA 
method. Among the 30 plasma samples tested, only 25 had a HA concentration comprised 
within the limit of quantification of the RIA method, as defined by the manufacturer (1 nM to 
100 nM). For these samples, an excellent correlation was revealed for HA concentrations 
determined by the two methods (r²=0.9198, Figure 3). Concerning the 5 remaining samples, 
HA concentration of 3 of them was measured superior to 100 nM using RIA and LCHRMS, 
and the 2 other samples were evaluated to have a HA concentration inferior to 1 nM with both 
methods. 
 
4. Discussion 
 
HA quantification is useful to confirm that clinical signs of a suspected anaphylaxis reaction 
result from the degranulation of tissue mast cells and blood basophils. This confirmation leads to 
a clinical and/or biological allergic investigation in order to find the offending allergen 
against which the patient is sensitized, allowing thereafter avoiding a new anaphylaxis reaction 
by the specific eviction of the allergen, or an induction of tolerance. HA quantification with 
the RIA gold standard method has the advantage to be highly sensitive, but requires the use 
of radioactive elements that implies the formation and the follow-up of the technicians, as 
well as the radioactive waste management, which is dangerous and expensive. Therefore, the 
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development of new methods presenting fewer disadvantages seems necessary. Methods using 
mass spectrometry are now commonly used in medical laboratories for quantification of drugs 
or metabolites. Recently, Liu J. et al described a UHPLC-MS/MS method for HA 
quantification in plasma of four different mammalian species including humans [21]. This 
method presents important advantages: low time-consuming, simple method. Unfortunately, 
blood samples were collected into tubes containing heparin sodium. However, it has been 
well-documented that heparin could bind to HA [22]; this phenomenon could then modify the 
free HA concentration measured by MS in the samples. The sensitivity of the method for HA 
quantification seems to be lower than for other methods classically used, due to a very low 
signal-to-noise ratio at the LLOQ value. In addition, a statistical correlation with obtained 
concentrations using RIA kits had not been determined. Furthermore, five plasma samples 
from healthy volunteers have been tested with this method. Plasma histamine amount is known 
to be physiologically very low in healthy patients. Nevertheless, in the reported study, two 
out of these five samples showed a HA concentration superior to 10 nM (12.7 nM and 24.7 
nM), concentration classically considered as the positive threshold value determining an HA 
release after mast cell and/or basophil degranulation. More recently, another LCMSMS 
method for HA quantification in rat plasma has been described by Chimalakonda K. et al [23]. 
With this method, the LLOQ was determined at 156 nM. However, this value is 15 fold 
higher than the positive threshold usually used for clinical diagnosis. Overall, these 
technically advantageous methods require some complementary experiments before being 
recommended in medical laboratories for a diagnostic use. 
In our study, High Resolution Accurate Mass LC-MS technology was chosen for HA 
quantification due to its high specificity and sensitivity for low molecular weight molecule 
quantification. Due to low amounts of HA physiologically found in plasma of healthy people, 
TrisBSA was used to mimic plasma HA-free matrix. Three QC samples were prepared by 
fortifying TrisBSA with HA: low at 3 nM HA, weakly positive at 30 nM HA, and highly 
positive at 150 nM HA. Recovery, matrix  effect  and process efficiency have also 
been tested in plasmas fortified with 3,  30 and 150  nM of HA. Process 
efficiency was similar between fortified plasma and TrisBSA (data not shown).  
Because HA concentrations over 100 nM reflect a massive mast cell and/or basophil 
degranulation and have no diagnostic interest, this value was chosen as the upper LOQ. The 
lower LOQ was determined at 1 nM, which is classically reported with other methods. For any 
steps of experiments, plastic containers were used, and glass surfaces were forbidden in order 
to avoid HA absorption, as described by Verburg and Henry [24]. Considering the extraction 
procedure, protein precipitation was performed using SSA. The mobile phase combined an 
increasing NFPA rate with an increasing flow rate in 5 min. Volatile ion-pair reagents 
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with long alkyl chain as NFPA are known to improve retention on ionisable 
polar compounds and to diminish matrix  effect  [25] . Moreover,  in 1996, 
Pearson et  al showed that the use of longer alkyl chained perfluorinated 
carboxylic acids may be an option to solve such problems [26].  The first 4 min 
were necessary to elute HA and the IS. The total run time of the method was set to 10 min in 
order to eliminate all interferences and re-equilibrate the column for the next injection. 
Between 2 injections, a 3 mL flush (75%ACN, 25% water containing 0.1% TFA) was 
necessary to minimized carryover. 
Simplification of sample preparation steps is crucial for a routinely medical laboratory use. 
However, most of HA quantification methods used for medical applications needs a 
derivatization step [7][14], leading to an increased risk of low analyte recovery, and extended 
sample preparation and analysis time. With High Resolution Accurate Mass LC-MS technology, 
derivatization, solid phase or extraction are not necessary. In addition, a limited volume of 
100 μL of plasma sample is sufficient to obtain a good sensitivity. 
Finally, the comparison of HA quantification using LCHRMS and RIA in plasma samples 
showed a very good correlation reinforcing the possibility to use our LCHRMS method in 
medical laboratory. Although results found by LCHRMS are well correlated with results 
obtained by RIA, some results are slightly underestimated with LCHRMS particularly 
for concentrations above 30 nM. We can discuss some hypotheses to explain 
these discrepancies. First ly,  because plasma samples have been analysed by RIA in 
2010 and by LCHRMS three years later, we could hypothesize that the underestimation 
obtained with LCHRMS could be explained by a possible degradation of HA during the 
prolonged storage at -80 °C. However, Laroche et al. reported that HA is stable in plasma for 
a period of at least 3 years at -20°C [27]. Secondly, according to the manufacturers’ 
data,  cross-reactivity with methyl histamine, the main metabolite of HA, is 
estimated at  0.069% with RIA. LCHRMS is the only assay that  can distinguish 
methyl histamine from HA. Thirdly,  LCHRMS calibration curve is l inear at 
least  from 1 to 240 nM (data not shown),  whereas RIA calibration curve is a 
semi-logarithmic. Considering samples with HA concentrations comprised 
between 30 and 100 nM, dots are situated at  the plat eau of the calibration 
curve (see graph below), which probably induces less precision and accuracy.  
Further investigations are underway to explore this underestimation with the LCHRMS 
method. Nevertheless, LCHRMS presents the advantage to avoid use of radioactivity. And even 
with a run time of 10 min per sample for a good metabolite separation, LCHRMS method 
remains still faster than RIA. 
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5. Conclusion 
 
In summary, we validated an original and specific LC-High Resolution-MS method for HA 
quantification in plasma samples. The Q ExactiveTM mass spectrometer was demonstrated to 
be suitable for routinely quantification in medical laboratories, and was less time-consuming 
than RIA, while exhibiting a similar sensitivity without derivatization step. We validated this 
LC-High Resolution-MS method for all the following parameters: linearity, matrix effect, 
precision, recovery and stability. In addition, this method was successfully applied to small 
plasma volumes.  
Overall, we report here a new method for histamine quantification in biological human plasmas 
using LCHRMS, suitable for routinely use in medical laboratories. Interestingly, LC-MS 
consumables are clearly safer and cheaper than those used for RIA. In addition, medical 
laboratories will try in a near future to avoid radioactivity use for safety issue. Then, despite the 
expensiveness of the device, we validate that LCHRMS could be a good candidate to replace 
RIA as the Gold Standard for HA quantification. 
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TABLES 
 
Time (minute) Solvent A (%) Solvent B (%) Flow rate (μL.min-1) 
0 10 90 400 
3 13 87 600 
5 53 47 600 
5.50 10 90 600 
7 10 90 400 
Table 1: Liquid chromatography gradient elution. Solvent A: NFPA (3 mmol.L-1). 
Solvent B: Acetonitrile with 0.1% (v/v) formic acid. 
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 Low (QC3) Middle (QC30) High (QC150) 
Theoretical concentration (nM) 3.0 30.0 150.0 
Measured concentration (nM) 2.9 30.7 151.4 
SD (nM) 0.1 1.3 4.4 
Intra-day CV (%) 2.3 4.1 2.9 
Bias (%) 4.1 2.4 0.9 
Table 2: Intra-day precision and bias for 3 levels of histamine QC samples (data are mean 
± SD, n = 6). (SD = Standard deviation, CV = coefficient of variation) 
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 Low (QC3) Middle (QC30) High (QC150) 
Theoretical concentration (nM) 3.0 30.0 150.0 
Measured concentration (nM) 3.0 31.7 159.1 
SD (nM) 0.3 1.9 5.4 
Inter-day CV (%) 8.7 6.1 3.4 
Bias (%) 0.2 5.6 6.1 
Table 3: Inter-day precision and bias for 3 levels of histamine QC samples (data are mean 
± SD, n = 10). (SD = Standard deviation, CV = coefficient of variation) 
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FIGURES 
 
 
Figure 1: Accurate mass spectra of the precursor and product ions of HA and HAd4. 
(A) The Molecular ion of protonated HA; (B) Majors fragments of HA; (C) Molecular 
ion of protonated HAd4; (D) Majors fragments of HAd4 
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Figure 2: Representative chromatograms obtained from human plasma. 
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Figure 3: Comparison of HA concentrations obtained by LC-High Resolution-MS 
analysis versus RIA. HA concentration of 25 plasma samples obtained from patients 
was measured using LCHRMS and RIA. 
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Highlights 
Q-Exactive mass spectrometer is suitable for routinely use in medical laboratories 
An LCHRMS method for histamine quantification has been developed for human 
plasma 
The LCHRMS method shows a good correlation with the gold standard RIA assay 
